You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨業績亮眼+美股大升,百濟神州高開超7%
百濟神州高開7.16%報106.2港元;隔夜美股市場百濟神州收升12.12%報179.69美元,折算成港股市場價格為108.24港元/股。公司此前公佈財報顯示,2023年第四季度總收入6.34億美元,同比增長67%;全年總收入25億美元,同比增長74%。百悦澤(澤布替尼)在血液學領域進一步鞏固領導地位,2023年第四季度全球銷售額4.13億美元,同比增長135%;全年全球銷售額13億美元,同比增長129%。受澤布替尼這一核心產品帶動,百濟神州2023年虧損收窄,歸母淨利潤由2022年虧損136.42億元大幅收窄至虧損67億元。業績公佈後,華泰證券稱其業績表現優異,給予其買入評級;BeiGene亦維持其買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.